FDA approves delivery of Cefepime in B. Braun's DUPLEX System

The U.S. Food and Drug Administration recently approved an application that permits B. Braun Medical Inc. (B. Braun) to deliver FDA-approved 1g and 2g Cefepime for Injection USP and Dextrose Injection USP in B. Braun's DUPLEX® Drug Delivery System.

Used in hospitals and healthcare centers to treat a wide variety of bacterial infections, Cefepime should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in the treatment of pneumonia, uncomplicated and complicated urinary tract infections, empiric therapy for febrile neutropenic patients, uncomplicated skin and skin structure infections, and complicated intra-abdominal infections. The availability of 1g and 2g Cefepime in the DUPLEX® System will mean faster, safer and accurate administration of Cefepime to patients as it can be stored ready-to-use in a container wherever and whenever it is needed.

"Making 1g and 2g Cefepime available to healthcare workers in B. Braun's DUPLEX® Drug Delivery System gives them another weapon to combat challenging infections with speed, safety and accuracy," said Rob Albert, Vice President of Marketing for B. Braun Medical Inc.

The DUPLEX® Drug Delivery System is a ready-to-use, two-compartment, flexible, eco-friendly IV container that stores pre-measured pharmaceuticals and diluent doses. DUPLEX® is easy to stock as it can be stored at room temperature, with 18-month minimum dating, and fits in automated medication dispensing systems. Unit dose-based DUPLEX® helps healthcare facilities achieve Joint Commission and USP Chapter < 797 > compliance that improves the practice of healthcare professionals while advancing patient safety.

Healthcare workers administering 1g or 2g Cefepime through DUPLEX® simply fold and squeeze the container and shake it to mix the pharmaceuticals and diluent. A barcode that references the final admixture, lot number and expiration date helps reduce medication errors, automate patient charting, track inventory and facilitate reimbursement tracking.

Source:

B. Braun Medical Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    B. Braun Melsungen AG. (2019, June 19). FDA approves delivery of Cefepime in B. Braun's DUPLEX System. News-Medical. Retrieved on March 30, 2020 from https://www.news-medical.net/news/20100512/FDA-approves-delivery-of-Cefepime-in-B-Brauns-DUPLEX-System.aspx.

  • MLA

    B. Braun Melsungen AG. "FDA approves delivery of Cefepime in B. Braun's DUPLEX System". News-Medical. 30 March 2020. <https://www.news-medical.net/news/20100512/FDA-approves-delivery-of-Cefepime-in-B-Brauns-DUPLEX-System.aspx>.

  • Chicago

    B. Braun Melsungen AG. "FDA approves delivery of Cefepime in B. Braun's DUPLEX System". News-Medical. https://www.news-medical.net/news/20100512/FDA-approves-delivery-of-Cefepime-in-B-Brauns-DUPLEX-System.aspx. (accessed March 30, 2020).

  • Harvard

    B. Braun Melsungen AG. 2019. FDA approves delivery of Cefepime in B. Braun's DUPLEX System. News-Medical, viewed 30 March 2020, https://www.news-medical.net/news/20100512/FDA-approves-delivery-of-Cefepime-in-B-Brauns-DUPLEX-System.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
You might also like... ×
B. Braun initiates voluntary recall of heparin injection products